The Filing Desk

Acadia Pharmaceuticals vs Madrigal Pharmaceuticals

Acadia Pharmaceuticals ACAD · Madrigal Pharmaceuticals MDGL · Pharmaceuticals

Acadia Pharmaceuticals reported revenue of $1.1 billion in fiscal 2025, about the same as Madrigal Pharmaceuticals' $958 million in fiscal 2025. Acadia Pharmaceuticals' revenue grew 11.9% in its latest year, and Madrigal Pharmaceuticals' grew 432.1%. Acadia Pharmaceuticals had an operating margin of 9.8%, against -31.3% at Madrigal Pharmaceuticals. Free cash flow was $105 million at Acadia Pharmaceuticals and −$190 million at Madrigal Pharmaceuticals.

Side by side

Acadia PharmaceuticalsMadrigal Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1.1B$958M
Revenue growth11.9%432.1%
Revenue growth a year, last 5 years19.4%—
Gross margin91.7%—
Operating margin9.8%−31.3%
Net margin36.5%−30.1%
Free cash flow$105M−$190M
Free cash flow margin9.8%−19.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count2.1%5.5%
Last close$17.59$396.74
P/E at the last close8.3×—
Insider trades, last 12 monthssold $2.5 millionsold $69.0 million
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Acadia PharmaceuticalsMadrigal Pharmaceuticals
Operating margin
Percent of revenue
Acadia PharmaceuticalsMadrigal Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Acadia PharmaceuticalsMadrigal Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Acadia Pharmaceuticals and Madrigal Pharmaceuticals pages.